A changing landscape in castration-resistant prostate cancer treatment

Frontiers in Endocrinology

Volumn 3, Issue JUL, 2012, Pages

  Felici, A ^a   Pino, M S ^b   Carlini, Paolo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Medical Oncology Unit   (Italy)

Author keywords

Abiraterone; Cabazitaxel; Castration resistance; Denosumab; Prostate cancer; Sipuleucel T

Indexed keywords

EID: 84874425541     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00085     Document Type: Review

References (53)

1. Acres, B., and Bonnefoy, J. Y. (2008). Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7, 889-893.
2. Amato, R. J., Drury, N., Naylor, S., Jac, J., Saxena, S., Cao, A., Hernandez-McClain, J., and Harrop, R. (2008). Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J. Immunother. 31, 577-585.
3. Arlen, P. M., Mohebtash, M., Madan, R. A., and Gulley, J. L. (2009). Promising novel immunotherapies and combinations for prostate cancer. Future Oncol. 5, 187-196.
4. Attard, G., Reid, A. H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., Olmos, D., Sinha, R., Lee, G., Dowsett, M., Kaye, S. B., Dearnaley, D., Kheoh, T., Molina, A., and de Bono, J. S. (2009a). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748.
5. Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Mor-eira, J., Riisnaes, R., Oommen, N. B., Hawche, G., Jameson, C., Thompson, E., Sipkema, R., Carden, C. P., Parker, C., Dearnaley, D., Kaye, S. B., Cooper, C. S., Molina, A., Cox, M. E., Terstappen, L. W., and de Bono, J. S. (2009b). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912-2918.
6. Attard, G., Reid, A. H., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., Clark, J., Cooper, C. S., Kaye, S. B., Dearnaley, D., Lee, G., and de Bono, J. S. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26,4563-4571.
7. Beer, T. M., Slovin, S. F., Higano, C. S., Tejwani, S., Dorff, T. B., and Stankevich, E. (2008). Phase I trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer. J. Clin. Oncol. 26(Suppl.), abstr. 5004.
8. Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., and Tan-nock, I. F. (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate-cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242-245.
9. Coffey, D. S., and Isaacs, J. T. (1981). Control of prostate growth. Urology 17, 17-24.
10. Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M. E., Bubley, G. J., Kheoh, T., Haqq, C., Molina, A., Anand, A., Koscuiszka, M., Larson, S. M., Schwartz, L. H., Fleisher, M., and Scher, H. I. (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496-1501.
11. Dayyani, F., Gallick, G. E., Logothetis, C. J., and Corn, P. G. (2011). Novel therapies for metastatic castrate-resistant prostate cancer. J. Natl. CancerInst. 103, 1665-1675.
12. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N.,Jones, R. J., Goodman, O. B. Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hut-son, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Stern-berg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., and Scher, H. I. (2011). Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005.
13. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., MacHiels, J. P., Kocak, I., Gravis, G., Bodrogi, I., MacKenzie, M. J., Shen, L., Roessner, M., Gupta, S., and Sartor, A. O. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154.
14. Di Lorenzo, G., Buonerba, C., Autorino, R., De Placido, S., and Sternberg, C. N. (2010). Castration-resistant prostate cancer current and emerging treatment strategies. Drugs 70, 983-1000.
15. Drake, C. G. (2010). Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10, 580-593.
16. Drake, C. G., Jaffee, E., and Pardoll, D. M. (2006). Mechanisms of immune evasion by tumors. Adv. Immunol. 90,51-81.
17. Dreicer, R., Stadler, W. M., Ahmann, E R., Whiteside, T., Bizouarne, N., Acres, B., Limacher, J. M., Squiban, P., and Pantuck, A. (2009). MVA MUC1 IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest. New Drugs 27, 379-386.
18. Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., and Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822.
19. Fong, L., Kwek, S. S., O'Brien, S., Kavanagh, B., McNeel, D. G., Wein-berg, V., Lin, A. M., Rosenberg, J., Ryan, C. J., Rini, B. I., and Small, E. J. (2009). Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF. Cancer Res. 69, 609-615.
20. Gulley, J. L., and Drake, C. G. (2011). Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17,3884-3891.
21. Hamberg, P., Verhagen, P. C., and de Wit, R. (2008). When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur. J. Cancer 44,1193-1197.
22. Higano, C. S., Schellhammer, P. F., Small, E. J., Burchm, P. A., Nemunaitis, J., Yuh, L., Provost, N., and Frohlich, M. W (2009). Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679.
23. Higano, C. S., Small, E. J., Schellhammer, P., Yasothan, U., Gubernick, S., Kirk-patrick,P.,and Kantoff,P. W. (2010). Sipuleucel-T. Nat. Rev. Drug Discov. 9,513-514.
24. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., and Urba, W. J. (2010). Improved survival with ipil- imumab in patients with metasta- tic melanoma. N. Engl. J. Med. 363, 711-723.
25. Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., and Vogelzang, N. J. (1999). Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17,2506-2513.
26. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., and Schell-hammer, P. E (2010a). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363,411-422.
27. Kantoff, P. W., Schuetz, T. J., Blumen-stein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., Dahut, W. L., Arlen, P. M., Gulley, J. L., God frey, and W. R. (2010b). Overall sur vival analysis of a phase II random ized controlled trial of a poxviral- based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105.
28. Li, J., Sarosi, I., Yan, X. Q., Morony S., Capparelli, C., Tan, H. L., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S. C., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C. R., Lacey, D. L., and Boyle, W. J. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U.S.A. 97, 1566-1571.
29. Liu, M. A. (2010). Immunologic basis of vaccine vectors. Immunity 33, 504-515.
30. Mizokami, A., Koh, E., Izumi, K., Nari-moto, K., Takeda, M., Honma, S., Dai, J., Keller, E. T., and Namiki, M. (2009). Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehy-droepiandrosterone. Endocr. Relat. Cancer 16, 1139-1155.
31. Mundy, G. R., Chen, D., Zhao, M., Dallas, S., Xu, C., and Harris, S. (2001). Growth regulatory factors and bone. Rev. Endocr. Metab. Dis-ord. 2,105-115.
32. Parker, C., Heinrich, D., O'Sullivan, J. M., Fossa, S. D., Chodacki, A., Demkow, T., Logue, J. P., Seke, M., Widmark, A., Johannessen, D. C., Nilsson, S., Hoskin, P., Solberg, A., James, N. D., Syndikus, I., Cross, A., O'Bryan-Tear, C. G., Gracia-Vargas, J. E., and Sartor, A. O. (2012a). Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metas-tases. J. Clin. Oncol. 30(Suppl. 5), abstr. 8.
33. Parker, C., Nilsson, S., Heinrich, D., O'Sullivan, J. M., Fossa, S. D., Chodacki, A., Wiechno, P. J., Logue, J. P., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottom-ley, D., Coleman, R. E., Vogelzang, N. J., O'Bryan-Tear, C. G., Gracia-Vargas, J. E., Shan, M., and Sartor, A. O. (2012b). Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J. Clin. Oncol. 30(Suppl.), abstr. LBA4512.
34. Petrylak, D. P., Tangen, C. M., Hus-sain, M. H., Lara, P. N. Jr., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., Benson, M. C., Small, E. J., Raghavan, D., and Crawford, E. D. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520.
35. Reid, A. H., Attard, G., Barrie,E., and de Bono, J. S. (2008). CYP17 inhibition as a hormonal strategy for prostate cancer. Nat. Clin. Pract. Urol. 5, 610-620.
36. Reid, A. H., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., Dearnaley, D., Swen-nenhuis, J. F., Terstappen, L. W., Lee, G., Kheoh, T., Molina, A., Ryan, C. J., Small, E., Scher, H. I., and de Bono, J. S. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abi-raterone acetate. J. Clin. Oncol. 28, 1489-1495.
37. Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D., and Chin-naiyan, A. M. (2002). Meta-analysis of microarrays: inter study validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 62, 4427-4433.
38. Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., Molina, A., and Small, E. J. (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration resistant prostate cancer who received prior ketocona-zole therapy. J. Clin. Oncol. 28, 1481-1488.
39. Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., and Chen, B. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94, 1458-1468.
40. Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., and Zheng, M. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 96,879-882.
41. Sartor, A. O., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fossa, S. D., Chodacki, A., Demkow, T., Logue, J. P., Seke, M., Widmark, A., Johannessen, D. C., Nilsson, S., Hoskin, P., Solberg, A., James, N. D., Syndikus, I., Vogelzang, N. J., O'Bryan-Tear, C. G., Shan, M., and Parker, C. (2012). Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA). J. Clin. Oncol. 30(Suppl. 5), abstr. 9.
42. Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M. E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., Hung, D., Hirmand, M., Seely, L., Morris, M. J., Danila, D. C., Humm, J., Larson, S., Fleisher, M., and Sawyers, C. L. (2010). Antitumour activity of MDV3100 in castration-resistant prostate can cer: a phase 1-2 study. Lancet 375, 1437-1446.
43. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics. CA Cancer J. Clin. 62,10-29.
44. Small, E. J., Schellhammer, P. F., and Higano, C. S. (2006). Placebo controlled phase III of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24,3089-3094.
45. Smith, M. R., Egerdie, B., Hernández Toriz, N., Feldman, R., Tammela, T. L., Saad, F., Heracek, J., Szwe-dowski, M., Ke, C., Kupic, A., Leder, B. Z., and Goessl, C. (2009). Deno- sumab in men receiving androgen- deprivation therapy for prostate cancer. N Engl. J. Med. 361, 745-755.
46. Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., and Balk, S. P. (2006). Increased expression of genes converting adrenal andro-gens to testosterone in androgen-independent prostate cancer. Cancer Res. 66,2815-2825.
47. Sternberg, C. N. (2008). Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann. Oncol. 19,vii91-vii95.
48. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., Rosen-thal, M. A., and Eisenberger, M. A. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl. J. Med. 351,1502-1512.
49. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., and Murphy, K. C. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756-1764.
50. Taylor, B. S., Varambally, S., and Chinnaiyan, A. M. (2006). Differential proteomic alterations between localized and metastatic prostate cancer. Br. J. Cancer 95, 425-430.
51. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., and Sawyers, C. L. (2009). Development of a second-generation antiandro-gen for treatment of advanced prostate cancer. Science 324, 787-790
52. Wang, X., Yu, J., Sreekumar, A., Varam-bally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., Kantoff, P. W., Rubin, M. A., Wei, J. T., Ghosh, D., and Chinnaiyan, A. M. (2005). Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224-1235.
53. Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., Humphrey, R., and Hodi, E S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420.